Sponsored

The OncLive® Sponsored section encompasses all sponsored content that is presented as articles, video interviews, webinars, blog posts, and more across various types of malignancies, including breast cancer, lung cancer, hematologic cancers, gynecologic cancers, gastrointestinal cancers, genitourinary cancers, and more.

Advancing Care in Metastatic Breast Cancer

June 3rd 2021

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Offers Subcutaneous CD38-Directed Antibody to Health Care Providers and Their Multiple Myeloma Patients

April 26th 2021

Since the U.S. Food and Drug Administration (FDA) approval of DARZALEX® (daratumumab) in 2015, the first CD38-directed antibody to treat multiple myeloma has been used in the treatment of more than 68,000 patients in the U.S. alone.

Multi-stakeholder collaboration: the catalyst for innovation in kidney cancer care

March 31st 2021

Applying RxPONDER to Clinical Practice

March 30th 2021

Faculty from the Miami Breast Cancer Conference® discuss how to apply the RxPONDER data to clinical practice.

More Can Be Done for Asian American Lung Cancer Patients

December 22nd 2020

Targeted Treatment Helps Delay ALK+ mNSCLC Progression

December 16th 2020

Remarkable progress has been made in the treatment of ALK+ mNSCLC patients, and the field continues to grow at a rapid pace.

Rethinking How We Approach Stage 3 Lung Cancer Treatment

October 20th 2020

As ongoing research continues to unlock the mechanisms of non–small cell lung cancer, it’s becoming increasingly clear that healthcare providers need to start rethinking how treatment is approached—especially for Stage 3 disease.

How Genomic Testing and Targeted Therapies Are Shifting the Mindset for Treating Acute Myeloid Leukemia

September 18th 2020

Questions and answers with Dr. Eunice Wang, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, an unpaid Astellas consultant

Delivering Long-Term Results for Blood Cancer Patients

July 21st 2020

While great progress has been made in developing and delivering new treatment options for chronic lymphocytic leukemia, recognizing the chronic nature of the disease and being cognizant of side effects that can have a major impact on a patient’s quality of life remains an important responsibility.

The Critical Role of Molecular Profiling in Cholangiocarcinoma

July 15th 2020

BiTE Platform and the Evolution Toward Off-The-Shelf Immuno-Oncology Approaches

June 2nd 2020

Amgen Oncology is committed to investigating innovative approaches to fighting cancer, across both hematological malignancies and solid tumors.

ASCO: New data for Alecensa shows 5-year overall survival in ALK-positive NSCLC

May 30th 2020

On Friday 29 May at the ASCO20 Virtual Scientific Programme, Roche presented updated data from the pivotal phase III ALEX clinical study.

Higher-Risk Myelodysplastic Syndromes: Lacking Treatment Advances in Over a Decade

May 4th 2020

Continued research is critical to potentially bring a targeted therapeutic option to patients with higher-risk myelodysplastic syndromes, to improve overall survival, manage symptoms, and preserve quality of life.

ESMO Data Show More Can Be Done for Cancer of Unknown Primary Patients

September 28th 2019

Two research papers presented by Roche and Foundation Medicine at the 2019 European Society of Medical Oncology (ESMO) Annual Meeting demonstrate both the promise of an innovative precision medicine driven clinical trial for patients with cancer of unknown primary, as well as the challenges of identifying eligible patients for the trial, according to ESMO guidelines.

The Importance of Genetic Testing in Ovarian Cancer: Diagnosis and Treatment

June 25th 2019

Angeles Alvarez Secord, MD, MHSc, discusses the importance of genetic testing and tumor testing in ovarian cancer and the potential impact on treatment decisions.

Biosimilars in Cancer Care: Potentially Improving Patient Access to Essential Therapies9,10

June 17th 2019

Gary Fanjiang, MD, vice president of Biosimilars Global Development, Amgen, discusses the development of biosimilars and some of the clinical considerations related to their use.

Seeking Ways to Extend Progression-Free Survival for Patients with Multiple Myeloma

March 5th 2019

New data presented at this year’s American Society of Hematology Annual Meeting showed that adding DARZALEX® (daratumumab) to standard of care multiple myeloma therapies may extend survival and achieve levels of minimal residual disease not previously seen.

YOUR Cancer Movement Spotlights Oncology HCPs and Community

January 13th 2019

Advancing cancer care requires more than just science. It’s a collective effort driven by passionate individuals and organizations dedicated to making a difference for those living with and affected by cancer.

TIL Therapy May Provide Second-Line Option for Cervical Cancer

October 25th 2018

Investigators are optimistic that LN-145, an autologous tumor-infiltrating lymphocyte investigational therapy, could be a potential treatment option for patients with recurrent, metastatic, or persistent cervical cancer.